Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mikhail M Kramchaninov"'
Autor:
Fedor V. Moiseenko, Mikhail Yu. Fedyanin, Nikita M. Volkov, Nuriniso Kh. Abduloeva, Natalya V. Levchenko, Vyacheslav A. Chubenko, Albina S. Zhabina, Maria L. Stepanova, Mikhail M. Kramchaninov, Elizaveta V. Artemeva, Vladimir M. Moiseyenko
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 50, Iss 1, Pp 47-55 (2022)
Rationale: Non-small cell lung cancer (NSCLC) is an aggressive disease with median survival of 1214 months in inoperable patients in the pre-immunotherapy era. Nowadays, under treatment with checkpoint inhibitors median survival is 1922 months. Howev
Externí odkaz:
https://doaj.org/article/8287edf3421a4498985c6a66a464a8e4
Autor:
Fedor V. Moiseyenko, Vitaliy V. Egorenkov, Mikhail M. Kramchaninov, Elizaveta V. Artemieva, Svetlana N. Aleksakhina, Maxim M. Holmatov, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 2, Pp 339-343 (2019)
Vemurafenib has been developed to target common BRAF mutation V600E. It also exerts activity towards some but not all rare BRAF substitutions. Proper cataloguing of drug-sensitive and -insensitive rare mutations remains a challenge, due to low occurr
Externí odkaz:
https://doaj.org/article/f3fe4fb603f74a8c8c7e0175c35ce4aa
Autor:
Artem Kosmin, Vadim Dmitriev, Aglaya G. Iyevleva, Tatiana N. Sokolova, Vladimir Moiseenko, Svetlana N. Aleksakhina, Evgeny N. Imyanitov, Tatiana Solovieva, Mikhail M Kramchaninov, Vladislav Petkau
Publikováno v:
Problems in oncology. 67:646-657
Background. More than half of breast carcinomas express estrogen and progesterone receptors (ER and PR) and remain estrogen-dependent. Endocrine therapy with inhibitors of the estrogen cascade allows long-term and effective control of the disease in
Autor:
Natalya Buevich, Daniil Stroyakovskiy, Tatyana Ionova, Rashida Orlova, Konstantin Laktionov, Fedor Moiseenko, N. Porfir’eva, Sergey Orlov, Mikhail M Kramchaninov, Valeriy Breder, Dilorom Latipova, Mariya Okruzhnova, Yelena Filippova, Ye. Kushniruk, Svetlana Protsenko, Anna Kornietskaya, Alla L. Arzumanyan, Larisa Bolotina, Anna Danilova, K. A. Sarantseva, Tatyana Nikitina, Anna Zinkovskaya
Publikováno v:
Problems in oncology. 65:99-105
The preliminary results of observational study focused on clinical efficacy and safety of nivolumab (Nivo) treatment as >2nd line in patients with advanced refractory NSCLC as well as on quality of life (QoL) before and during treatment are presented
Autor:
Tatyana N. Sokolova, Fedor V. Moiseyenko, Alexey A Kudriavtsev, Aglaya G. Iyevleva, Natalia V. Mitiushkina, Mikhail M Kramchaninov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Nikita M. Volkov, Elena V. Preobrazhenskaya, Kseniya S. Kozyreva, Kseniya V. Shelekhova, Ilya V. Bizin, Alexandr S. Zhuravlev, Ekatherina Sh. Kuligina, Aigul R. Venina, Evgeny N. Imyanitov, Denis V Pashkov, Anna P. Sokolenko, Vyacheslav A. Chubenko, Vladimir M. Moiseyenko, Alexandr V. Togo
Publikováno v:
Clinical Drug Investigation. 38:553-562
Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF). Most clinical trials for chemo-naive CRC p
Autor:
A S Zhabina, N. Kh. Abduloeva, E.M. Zykov, Vyacheslav A. Chubenko, Mikhail M Kramchaninov, E.V. Napolskaya, Fedor Moiseenko, Anna Meldo, Vladimir M. Moiseyenko, A.A. Kudryavcev, Ludmila Zagorskaya, Ksenia Shelekhova, V. Chubenko
Publikováno v:
Practical oncology. 20:289-288
Autor:
Rashida Orlova, Svetlana Protsenko, Anna Kornietskaya, Larisa Bolotina, Dilorom Latipova, Sergey Orlov, Daniil Stroyakovskiy, Tatiana Nikitina, Evgeny Ledin, Anna Zinkovskaya, Tatyana Ionova, Anastasia Mochalova, E. Filippova, Eugenia K Kushniruk, Anastasia Danilova, Ksenia A. Sarantseva, Mikhail M Kramchaninov, Fedor Moiseenko, Konstantin Laktionov, Valeriy Breder
Publikováno v:
Journal of Clinical Oncology. 37:e20567-e20567
e20567 Background: We aimed to evaluate clinical and quality of life (QoL) outcomes of Nivo as 2+ line treatment in NSCLC pts within expanded access program and real world practice. Methods: Adult pts with advanced refractory NSCLC were enrolled in 1
Autor:
Tatyana Ionova, Konstantin Laktionov, Dilorom Latipova, Valeriy Breder, Svetlana Protsenko, Anna Kornietskaya, Rashida Orlova, Mikhail M Kramchaninov, Natalia N. Buevich, Eugenia K Kushniruk, Anna Zinkovskaya, Alla L. Arzumanyan, Ksenia A. Sarantseva, Sergey Orlov, Daniil Stroyakovskiy, Larisa Bolotina, Fedor Moiseenko, Elena A. Filippova, Anastasia Danilova, Tatiana Nikitina
Publikováno v:
Journal of Clinical Oncology. 36:e21126-e21126
e21126Background: We aimed to evaluate quality of life (QoL) in advanced refractory NSCLC pts and clinical outcomes of nivolumab (Nivo) as ≥ 2nd line treatment within the expanded access program in...
Autor:
Larisa Bolotina, Daniil Stroyakovskiy, Valeriy Breder, Dilorom Latipova, Rashida Orlova, Daria A Lipatova, Fedor Moiseenko, Anastasia Danilova, Elena A. Filippova, Tatiana Nikitina, Ksenia A. Sarantseva, Konstantin Laktionov, Sergey Orlov, Tatyana Ionova, Natalia N. Buevich, Eugenia K Kushniruk, Svetlana Protsenko, Anna Kornietskaya, Mikhail M Kramchaninov, Alla L. Arzumanyan
Publikováno v:
Journal of Clinical Oncology. 35:e14593-e14593
e14593 Background: Therapy with immune checkpoint inhibitors (ICI) changed the paradigm of treatment in many solid tumors including NSCLC. Recently several ICI were approved for NSCLC second and first line. By now data on Nivo benefits/risks in NSCLC
Autor:
Anna Meldo, Nuriniso Kh. Abduloeva, Elena Napolskaya, A S Zhabina, Valentina Lukyanchikova, Evgenii Zykov, Ksenia Shelekhova, Viacheslav Chubenko, Ludmila Zagorskaya, Mikhail M Kramchaninov, Vladimir Moiseyenko, Fedor Moiseenko, Alexey Kudryavcev, Natalia Levchenko
Publikováno v:
Web of Science
e15519 Background: Metronomic therapy (MT) is one of the most promising advances in cancer treatment strategy focused on both tumor cells and their microenvironment, specifically anti-angiogenic, immune and metabolic regulation. The treatment modalit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74acb35c0b6e2eb6b39aed5e4a707d88
https://publons.com/wos-op/publon/46596004/
https://publons.com/wos-op/publon/46596004/